New therapeutic options in neurogastroenterology and motility -areas that affect many patients but with few available treatments -also appear promising. Symptomatic benefits were demonstrated for the selective 5-hydroxytryptamine4 receptor agonist prucalopride, and the peripherally-acting mu-opioid receptor antagonist, naloxegol.
There was fascinating new evidence of a beneficial effect of a probiotic on comorbid depression and brain emotional reactivity in patients with irritable bowel syndrome. Specific microbes also appear to benefit patients with ulcerative colitis: certain bacterial signatures present after faecal microbiota transplantation are linked to a sustained response to treatment.
To read more about UEG Week 2015 and its many scientific highlights access the Post Congress Report on http://www.ueg.eu/UEGWeek.2015.PostCongress News/!
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